Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Takeda Pharmaceutical (NYSE:TAK – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.
Risk and Volatility
Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Alpha Cognition and Takeda Pharmaceutical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
| Takeda Pharmaceutical | 0 | 1 | 2 | 1 | 3.00 |
Profitability
This table compares Alpha Cognition and Takeda Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
| Takeda Pharmaceutical | 3.80% | 10.95% | 5.34% |
Institutional & Insider Ownership
9.2% of Takeda Pharmaceutical shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Alpha Cognition and Takeda Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | $15.26 million | 12.09 | -$20.67 million | ($1.10) | -7.70 |
| Takeda Pharmaceutical | $4,618.94 billion | 0.01 | -$1.01 billion | $0.34 | 55.43 |
Alpha Cognition has higher earnings, but lower revenue than Takeda Pharmaceutical. Alpha Cognition is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Takeda Pharmaceutical beats Alpha Cognition on 8 of the 14 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
